Biohaven Ltd. (BHVN)
| Market Cap | 1.69B +1.7% |
| Revenue (ttm) | n/a |
| Net Income | -647.68M |
| EPS | -5.44 |
| Shares Out | 150.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 339,556 |
| Open | 11.33 |
| Previous Close | 11.40 |
| Day's Range | 11.17 - 11.50 |
| 52-Week Range | 7.48 - 18.57 |
| Beta | 3.30 |
| Analysts | Buy |
| Price Target | 21.71 (+93.75%) |
| Earnings Date | May 4, 2026 |
About BHVN
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for BHVN stock is "Buy." The 12-month stock price target is $21.71, which is an increase of 93.75% from the latest price.
News
Biohaven initiates first-in-human dosing for BHV-8100
Biohaven (BHVN) announced the initiation of first-in-human dosing for BHV-8100, its oral, brain-penetrant pyruvate kinase M2 isoform modulator. Dr. Bruce Car, Chief Scientific Officer of Biohaven, sta...
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system disorders Fir...
Biohaven’s candidates in Graves’ Disease and IgA nephropathy shows efficacy
Biohaven (BHVN) reported “compelling” results regarding its proprietary extracellular MoDE – BHV-1300 – and TRAP – BHV-1400 – degrader platform. Key highlights from the Phase 1b Graves’ Disease patien...
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
BHV-1300 demonstrated deep, rapid, and sustained lowering of pathogenic TSHR autoantibodies (TSHR-IgG1) in patients with Graves' hyperthyroidism receiving 1000 mg SC weekly, with mean reductions in TS...
Biohaven reports data from selective Kv7.2/7.3 channel activator program
Biohaven (BHVN) reported new data from its selective Kv7.2/7.3 channel activator program, currently in Phase 2/3 studies for the treatment of focal epilepsy, and will present additional updates at its...
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a generalized tonic-clonic seizure was 141 days in the opakali...
Biohaven price target lowered to $18 from $21 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Biohaven (BHVN) to $18 from $21 and keeps an Overweight rating on the shares.
Biohaven price target lowered to $22 from $23 at RBC Capital
RBC Capital lowered the firm’s price target on Biohaven (BHVN) to $22 from $23 and keeps an Outperform rating on the shares. The company’s Q1 results indicate that programs are…
Biohaven price target lowered to $12 from $14 at BofA
BofA lowered the firm’s price target on Biohaven (BHVN) to $12 from $14 and keeps a Neutral rating on the shares. The firm views the company’s Q1 report as largely…
Biohaven files automatic mixed securities shelf
16:27 EDT Biohaven (BHVN) files automatic mixed securities shelf
Biohaven reports Q1 adjusted EPS (69c), consensus (76c)
Reports Q1 R&D expenses, including non-cash share-based compensation costs, $103.8M, compared to $187.6M last year. Vlad Coric, Chairman and CEO of Biohaven (BHVN), commented, “We are planning for a t...
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026. Advancement of high-value, late-stage priority programs: Piv...
Biohaven Quarterly report: Q1 2026
Biohaven has published its Q1 2026 quarterly earnings report on May 4, 2026.
Biohaven Earnings release: Q1 2026
Biohaven released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.
Biohaven initiated with a Buy at Canaccord
Canaccord initiated coverage of Biohaven (BHVN) with a Buy rating and $21 price target The company is developing novel therapeutics for immunology, obesity, neuroscience and oncology indications, the ...
Biohaven price target raised to $17 from $14 at Citi
Citi analyst Samantha Semenkow raised the firm’s price target on Biohaven (BHVN) to $17 from $14 and keeps a Buy rating on the shares. The firm sees an attractive risk/reward…
Biohaven completes enrollment in Phase 2 study on taldefgrobep alfa
Biohaven (BHVN) announced the completion of enrollment in a Phase 2 proof-of-concept study with its myostatin-activin pathway inhibitor, taldefgrobep alfa, which offers the potential to achieve high-q...
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026. Taldefgrobep is a novel inhi...
Biohaven Proxy statement: Proxy Filing
Biohaven filed a proxy statement on March 13, 2026, providing details for shareholder voting and corporate governance matters.
Biohaven Proxy statement: Proxy Filing
Biohaven filed a proxy statement on March 13, 2026, providing details for shareholder voting and corporate governance matters.
Biohaven price target raised to $30 from $15 at TD Cowen
TD Cowen analyst Ken Cacciatore raised the firm’s price target on Biohaven (BHVN) to $30 from $15 and keeps a Buy rating on the shares. The firm updated its model…
Biohaven price target raised to $27 from $24 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Biohaven (BHVN) to $27 from $24 and keeps a Buy rating on the shares. Xenon (XENE) reported strong Phase 3 X-TOLE2 results…
Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate
Raymond James keeps a Strong Buy rating on Biohaven (BHVN) shares following competitor Xenon Pharmaceuticals’ (XENE) top-line Phase 3 readout for Kv7 modulator azetukalner showing efficacy in-line wit...
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM) extracellular protein degradation...
Biohaven Annual report: Q4 2025
Biohaven has published its Q4 2025 annual report on March 2, 2026.